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Obesity is a pan-endemic health problem in both
developed and developing countries and is asso-
ciated with considerable increase in morbidity and
mortality.1–3 For the severely obese patient, nonsur-
gical methods (including diet, exercise, and behav-
ioral modification) are usually ineffective and
rarely result in sustained weight loss.4,5 Surgery 
is the only treatment that has been proven to
consistently achieve long-term reduction of excess
weight in patients with severe clinical obesity.4–6
gLaparoscopic adjustable gastric bandin
(LAGB) is a minimally invasive surgical procedure
for the treatment of morbid obesity. Kuzmak devel-
oped the adjustable silicone gastric band, which
was implanted via laparotomy.7 In 1993, a modi-
fied laparoscopic device, the Lap-Band (Bioenterics
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Corp., Carpinteria, CA, USA) was first implanted
(Figure 1).8 Initial trials in Europe and worldwide
use were expanded later.9–13 In June 2001, the US
Food and Drug Administration approved the Lap-
Band System in the United States. Currently, LAGB
is the most commonly performed bariatric surgery
worldwide.6
This report describes our series of 91 con-
secutive Taiwanese patients, making this the first 
clinical trial in Taiwan.
Materials and Methods
A comprehensive, multidiscipliniary, bariatric man-
agement program was in place for the preoperative
preparation and postoperative management of pa-
tients. The program included support groups and
ancillary personnel to provide nutritional, exercise
and psychologic care. Nurse specialists for medical
and psychiatric management were part of the team.
Inclusion/exclusion criteria followed the standard
National Institutes of Health guidelines: >18 years
old, body mass index (BMI) >35 kg/m2 with im-
portant comorbidities, no alcohol abuse and con-
fcurrent psychiatric illness. The ethics committee o
En-Chu-Kong Hospital and the National Depart-
ment of Health of Taiwan approved this trial.
yPatients were placed supine in the lithotom
position, then to the reverse Trendelenburg po-
Asition, and an orogastric tube was inserted. 
five-trocar technique was used (Figure 2). Pneu-
moperitoneum was achieved with a Veress-type
needle introduced at the supraumbilical area and
maintained at 15 mmHg. All bands were placed
using the pars flaccid technique.5 Briefly, the
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iF gure 1. (A) The Lap-Band system with inflatable inner cuff (arrow) that connects by silicon tubing to the implanted 
subcutaneous injection port (arrowhead). (B) Drawing shows placement of the band around the upper portion of the
stomach, creating a small upper pouch with stoma to the remainder of the stomach.
A B
iF gure 2. f(A) Trocar placement. Trocar 1: a 15-mm port about 4 cm above the umbilicus, rom the midline to across the
left rectus muscle, viewing telescope and injection port site. Trocars 2 and 4 are placed in the bilateral subcostal areas
with 5 mm for bilateral working ports. Trocar 3: a 5-mm port placed subxyphoidal, liver retractor. Trocar 5: a 10-mm port
at the left anterior axillary line, gastric grasper. (B) Intraoperative picture.
dissection began at the Angle of His. A very small
opening was created in the avascular phrenogas-
tric ligament, close to the gastric wall at the Angle
of His. The dissection was then moved to the lesser
curvature side. The pars flaccid (gastrohepatic
ligaments) was incised and the right crus of the
diaphragm was identified. Blunt dissection was
performed to create a passage between the dia-
phragmatic pillars and the posterior aspect of the
gastroesophageal junction. The band was then
placed around the cardia of the stomach and su-
tured in place with gastric to gastric sutures. The
band tubing was brought outside the abdomen
and connected to the access port. The port was
fixed to the left rectus fascia.
The surgeon, with the support of the nurse
coordinator and nutritionist, provided postoper-
ative follow-up. After discharge, patients were in-
structed to follow a clear to full liquid diet for the
first 48 hours, followed by a soft diet for the first
week. Small amounts of solid food were intro-
duced starting in the second week, as tolerated.
Patients returned to the office a week after surgery
for wound check. They were then scheduled to re-
turn between 1 and 2 months later. For adjust-
ment of the LAGB, saline was not added to the
band reservoir until at least 4 weeks had elapsed
after surgery. We routinely performed adjustments
in the clinic. Computed tomography (CT)-guided
adjustment was only indicated occasionally. The
first adjustment usually involved the addition of
1 mL of sterile saline. The second adjustment 
involved the addition of 0.5 mL when patients
failed to lose weight but had sustained satiety 
between meals.
Prior to surgery, all patients underwent a
thorough laboratory work-up including meta-
bolic profile and complete blood count with in-
dices. For the purpose of comorbidity assessment,
patients (n = t56) who had completed at leas  
12 months of follow-up were included. Obesity-
grelated illness status was assessed by comparin
each comorbidity before surgery and 1 year later.
Criteria used to define metabolic comorbidities
are listed in Table 1.
Descriptive data are expressed as mean ±
standard deviation. Group characteristics were
compared by the paired t test and differences
between proportions were tested by the χ2 test.
Statistical analysis was performed using SPSS 
rversion 8.0 (SPSS Inc., Chicago, IL, USA) fo
yWindows. Statistical significance was inferred b
a two-tailed p value of less than 0.05.
Results
Between May 2002 and May 2005, LAGB was
performed on 91 consecutive patients. There were 
f 47 men and 44 women, with a mean age o
f 31.2 years (range, 18–56 years) and mean BMI o
42.7 kg/m2 (range, 35.0–62.7 kg/m2). Of the
91 patients, 80 suffered from obesity-related co-
morbidities such as hypertension, diabetes, hy-
perlipidemia, arthritis, asthma, sleep apnea and
venous stasis (Table 2). The mean operating time
was 88.7±32.9 minutes. The mean operating time
for the first 10 cases was 107 minutes, and it was
r83 minutes for the last 10 cases. There was neithe
conversion nor major complication in this series.
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Table 1. Definition criteria of obesity-related comorbidities
Comorbidity Definition
Hypertension Blood pressure > 140/90 mmHg or previous diagnosis of hypertension on 
pharmacologic treatment
Hyperglycemia Fasting glycemia > 109 mg/dL or previous diagnosis of diabetes on pharmacologic 
treatment
Hyperlipidemia Fasting triglycerides > 200 mg/dL and/or cholesterol > 200 mg/dL
Hyperuricemia Fasting uric acid > 8.0 mg/dL in men and > 6.5 mg/dL in women
Abnormal liver function Aspartate aminotransferase > 40 IU/dL and/or alanine aminotransferase > 40 IU/dL
W.J. Lee, et al
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Minor complications occurred in three (3.3%) pa-
tients, all were transient stoma obstruction and
subsided after conservative treatment (Figure 3).
Hospital stay averaged 3.2 days (range, 2–10 days).
Patient follow-up
Of the 91 patients, the follow-up rate was 100%.
Late complications occurred in seven (7.7%)
t patients. One (1.1%) had her band removed a
3 months postoperatively due to intractable vomit-
ring. Four (4.4%) received port revision surgery fo
tubing problems. Another patient had acute food
obstruction and required admission for treatment.
No band was removed in these patients. The ma-
jority of patients received two to five band adjust-
ments during the first year after surgery. tAlmos
Table 2. Preoperative and follow-up clinical data of patients who underwent laparoscopic adjustable
gastric banding
Preoperatively
Postoperatively
3 mo 6 mo 1 yr 2 yr
Weight (kg) 120.8 110.2 109.9 101.3 97.4
BMI (kg/m2) 42.7 38.1 37.4 35.3 34.9
Hypertension (%) 47.3 63.8 46.9 48.1 40.1
Hyperglycemia (%) 17.6 9.5 4.6 0 0
Hyperlipidemia (%) 64.8 41.3 34.1 34.2 30.8
Hyperuricemia (%) 60.4 28.6 20.9 8.8 0
Abnormal LF (%) 20.9 8.8 1.1 2.2 0
Arthritis (%) 4.4 12.6 5.6 0 0
Asthma (%) 3.3 1.1 0 0 0
Sleep apnea (%) 8.8 1.6 0 0 0
Venous stasis (%) 3.3 1.6 0 0 0
Satisfaction (%)
Excellent 63 60 50 43
Good 24 28 35 37
Acceptable 10 8 9 14
Bad 2 4 6 6
Poor 1 0 0 0
BMI = body mass index; LF = liver function test.
A B
iF gure 3. ( ) l d h f l f h l d bl b d ( ) hA  Upper gastrointestina  ra iograp  a ter p acement o  t e aparoscopic a justa e gastric an  LAGB  wit
normal stoma. (B) Upper gastrointestinal radiograph of stoma stenosis after LAGB placement.
all patients required their first band adjustment
within the first 3 months after surgery. Seven pa-
tients required CT-guided adjustment due to
malposition of the port or massive subcutaneous
fat (Figure 4).
Weight loss and comorbidity assessment
After a median follow-up of 30 months, the group
had a significant reduction in BMI (Figure 5).
Mean preoperative BMI was 42.7 kg/m2 and had
decreased to 33.9 kg/m2 3 years after LAGB. Mean
body weight decreased from 120.8 kg to 94.7 kg.
Mean BMI and (reduction of excess BMI as com-
pared to BMI = 25 kg/m2) were 38.8 (22.1%), 37.4
(29.7%), 35.1 (41.7%), 34.9 (44.0%) and 33.9
(44.8%) at 3, 6, 12, 24 and 36 months, respec-
tively. At 2 years after LAGB, all obesity-related
ycomorbidities had been eliminated significantl
except for hypertension (Table 2). Table 3 shows
the changes in various clinical variables before
and 1 year after LAGB. Recovery from diabetes,
hypertriglyceridemia, abnormal liver function
and hyperglycemia were more favorable, whereas
recovery from hypertension did not differ. The
white blood cell count also decreased signifi-
cantly after surgery. There was no detectable dif-
ference in calcium metabolism, hemoglobin,
and albumin levels pre- and postoperatively.
Laparoscopic adjustable gastric banding
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iF gure 4. bd l d h ( ) h ( ) b fl h bA omina  compute  tomograp y CT  s ows: A  su cutaneous injection port oating in t e massive su -
cutaneous fat (arrow); and (B) tilting injection port (arrow). Both cases required CT-guided injection for adjustment.
42.7
38.8
37.4
34.1
34.935.3
30
32
34
36
38
40
42
44
Before 3
Months
6 9 1 2 3 
B
od
y 
m
as
s 
in
de
x 
(k
g/
m
2 )
Years
iF gure 5. h b d d d l d bl b dC ange in o y mass in ex pre- an  post- aparoscopic a justa e gastric an ing.
Table 3. Laboratory data before and 1 year after laparoscopic adjustable gastric banding
Preoperatively 1 yr postoperatively p
BMI (kg/m2) 42.7 ± 6.0 35.3 ± 6.6 < 0.001*
SBP (mmHg) 136.9 ± 22.7 140.8 ± 22.4 0.870
DBP (mmHg) 85.5 ± 13.4 85.7 ± 18.5 0.566
Glucose (mg/dL) 105.2 ± 36.2 84.6 ± 8.1 0.040*
TC (mmol/L) 198.0 ± 35.9 189.8 ± 31.3 0.017*
HDL-C (mmol/dL) 44.02 ± 13.1 50.6 ± 12.7 0.018*
TG (mg/dL) 188.5 ± 148.6 101.4 ± 45.9 0.008*
Uric acid (mg/dL) 7.69 ± 1.69 6.66 ± 1.44 < 0.001*
AST (IU/L) 33.5 ± 23.4 23.4 ± 9.6 0.004*
ALT (IU/L) 51.5 ± 44.7 25.2 ± 16.2 < 0.001*
RGT (IU/L) 46.7 ± 32.9 24.9 ± 11.1 0.017*
Albumin (g/dL) 4.75 ± 0.31 4.36 ± 0.26 0.514
T-protein (g/dL) 7.4 ± 1.3 7.4 ± 0.4 0.219
ALP (IU/L) 75.7 ± 27.5 55.1 ± 47.7 0.393
Ca (mg/dL) 8.9 ± 0.4 9.0 ± 0.4 0.858
WBC (103/μL) 8.70 ± 2.30 6.87 ± 1.53 < 0.001*
Hemoglobin (g/dL) 14.1 ± 1.67 14.1 ± 1.8 0.383
MCV 85.6 ± 6.9 86.8 ± 6.8 0.411
Insulin (pmol/L) 22.5 ± 20.5 8.02 ± 4.44 0.007*
C-peptide (mmol/L) 3.91 ± 2.76 2.28 ± 0.82 0.020*
HbA1C (IU/L) 6.2 ± 1.2 5.3 ± 0.4 0.002*
*p < 0.05. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; TC = total cholesterol; HDL-C; high-
density lipoprotein cholesterol; TG = triglycerides; AST = aspartate aminotransferase; ALT = alanine aminotransferase; RGT = gamma-
glutamyl transpeptidase; ALP = alkaline phosphatase; WBC = white blood cell; MCV = mean corpuscular volume; HbA1C = glycosylated
hemoglobin.
Discussion
This is the first prospective study of LAGB in
Taiwan and Asia. The present study confirmed that
LAGB is a safe and effective minimally invasive
bariatric surgical procedure suitable for use in
Asians. In our experience, LAGB could be per-
formed with a 0% major complication rate and
3.3% minor complication rate, which are compat-
ible with other reports.9–14 The only early compli-
cation in this study was postoperative transient
esophageal stenosis due to the band being too
small for the super-obese patient. This complica-
tion can be avoided either by removal of the thick
fat pad over the His angle or by using a larger band.
All the three incidences of this complication in our
study occurred before the introduction of a larger
LAGB (the Vanguard Lap-Band system). This com-
plication was avoided thereafter. Before the matu-
ration of this technique, the late complication rate
was reported to be up to 30%, including slippage,
band erosion and tube failure.8 In this study, no
slippage, band erosion or port infection was ob-
served up to 2 years postoperatively, and only one
band (1.1%) has been removed up till now.
Results of LAGB in the West have shown
that good weight loss and significant reduction
in obesity-related illness can be achieved. Inter-
national experience with the LAGB in Europe and
Australia shows a reduction in BMI of 9–13 kg/m2
from baseline within 2 years of placement.9–14
Weight loss continues even up to 5 years after sur-
gery and stabilizes up to 9 years of follow-up.9–14
Data from the United States are controversial. An
initial trial reported a mean BMI reduction of 8.7
over 3 years and 28% of the LAGB were removed
because of complications.15 However, with im-
provements in the techniques, some recent studies
have reported similar data to the international
experience.16,17 The mean BMI reduction of 8.8
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and late complication rate of 7.7% in this series
are consistent with other studies.
Vertical banded gastroplasty (VBG) has been a
popular bariatric operation in Taiwan for the past
two decades, and results have shown the procedure
to be effective over a 15-year follow-up.18 After 
a report of the feasibility of laparoscopic VBG
(LVBG),19 we conducted a retrospective study com-
paring conventional VBG and LVBG, and con-
cluded that LVBG was a better procedure because
of less pain, shorter hospital stay and less wound
complications.20 However, VBG has some notori-
ous long-term problems, such as regain of weight,
vomiting, and impairment of gastrointestinal
quality of life. In an analysis by van Germert 
et al, up to 56% of VBG patients needed revisional
surgery over a period of 12 years.21 In our 5-year
follow-up, the revision rate was 9.2%, which is
compatible with the reported results for conven-
tional VBG.22,23 LAGB, as an alternative restrictive
procedure, has the benefits of simpler standard-
ized procedure, fewer complications, and sus-
tained weight loss due to its adjustability. Our
study confirmed the safety of LAGB and sustained
weight loss up to 3 years. The mean operation time
is also shorter in LAGB than in LVBG, 88.3 minutes
versus 173 minutes.20 Although the results of
weight reduction are similar between LAGB and
LVBG, the 0% major complication rate and 3.3%
minor complication rate of LAGB are lower than
the 1% major complication rate and 5% minor
complication rate of LVBG. The revision rate of
LAGB is 1.3%, which is also lower than the 9.2%
revision rate of LVBG.22,23 Therefore, we strongly
recommend LABG to replace LVBG in Taiwan.
Laparoscopic gastric bypass (LGB) is another
common surgical procedure for morbidly obese
patients and is the most commonly performed
bariatric procedure in the United States.5 Although
LGB is more effective than LVBG, the complication
rate is higher than that of LVBG. In our previous
study, we found that LGB is much more difficult
in terms of technique and carried more than three
times the risk of major complications than VBG.24
The learning curve for LGB is also much steeper
than for LAGB. For example, the complication rate
for a surgeon performing the first 19 cases was
greported to be four times higher than performin
the procedure after 20 cases.25 In our series, the
learning curve of LAGB is 10 cases, which is much
lower than the 20 cases for LGB.24 Although LGB
rresults in better weight reduction than LVBG o
fLAGB, there is no difference in the resolution o
obesity-related comorbidities.26 cBecause bariatri
surgery in Asia is still in its infancy, how laparo-
scopic bariatric surgery can be performed safely is
the most important current issue. Therefore, LAGB
is the recommended primary bariatric procedure
for Asian people at present.27
The well-known inverse relationship between
life expectancy and obesity is presumably, in large
part, due to multiple cardiovascular and meta-
bolic comorbidities. Our previous study disclosed
a higher prevalence of metabolic abnormalities
tin obese Taiwanese patients referred for weigh
reduction surgery.28 tHowever, significant weigh
reduction 1 year after surgery markedly improved
all aspects of the metabolic syndrome and resulted
in a cure rate of over 95%.26 This study confirmed
the efficacy of bariatric surgery in the resolution
of obesity-related comorbidities except hyperten-
sion. The possible explanation for this might be
that the case number is small and the procedure is
different compared to our previous report.26 The
rfollow-up is also short when compared to anothe
study.29 As hypertension has a more complicated
mechanism than the other metabolic complica-
 tions of obesity, ethnic differences may also be
a possible explanation.30,31
yCurrent indications for surgery in morbidl
obese patients include BMI > 40 kg/m2 or > 35
kg/m2 if comorbidities are present. However, these
criteria are based on data from Caucasians.4 tI
has been amply demonstrated that Asians, in
general, have a higher percent of body fat at a
given BMI than Caucasians.30,31 Morbidities and
mortality among Asians occur at lower BMIs and
csmaller waist circumferences. The Asia-Pacifi
Bariatric Surgery Group has recently recom-
mended bariatric surgery in Asian patients with
BMI > 37 kg/m2 or > 32 kg/m2 when diabetes 
or two other obesity-related comorbidities are
Laparoscopic adjustable gastric banding
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present.26 Cost-effectiveness studies of LAGB in the
treatment of severely obese patients are needed.
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